ZIOPHARM Oncology Inc. (ZIOP)

3.94
NASDAQ : Health Technology
Prev Close 3.96
Day Low/High 3.77 / 3.98
52 Wk Low/High 1.56 / 7.25
Avg Volume 1.78M
Exchange NASDAQ
Shares Outstanding 162.55M
Market Cap 643.71M
EPS -0.50
P/E Ratio 3.74
Div & Yield N.A. (N.A)

Latest News

Interesting ZIOP Put And Call Options For November 15th

Interesting ZIOP Put And Call Options For November 15th

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the November 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new November 15th contracts and identified one put and one call contract of particular interest.

ZIOPHARM Oncology Becomes Oversold (ZIOP)

ZIOPHARM Oncology Becomes Oversold (ZIOP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of ZIOP January 2022 Options Trading

First Week Of ZIOP January 2022 Options Trading

Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the January 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 857 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ziopharm Oncology To Participate In The Morgan Stanley 17th Annual Global Healthcare Conference

Ziopharm Oncology To Participate In The Morgan Stanley 17th Annual Global Healthcare Conference

BOSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc.

Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc.

First Week Of ZIOP April 2020 Options Trading

First Week Of ZIOP April 2020 Options Trading

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the April 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

5 Favorites for Biotech Stock Buyers

5 Favorites for Biotech Stock Buyers

For those with a long-term horizon, here are some top picks.

Ziopharm Oncology Announces Publication Of Positive Results Of Phase 1 Monotherapy Trial Of Controlled IL-12 In Patients With Recurrent Glioblastoma In Science Translational Medicine

Ziopharm Oncology Announces Publication Of Positive Results Of Phase 1 Monotherapy Trial Of Controlled IL-12 In Patients With Recurrent Glioblastoma In Science Translational Medicine

- Ad-RTS-hIL-12 plus 20 mg veledimex (Controlled IL-12 platform) determined to be the preferred dose with low-dose steroids to treat adult patients with recurrent glioblastoma - - Median overall survival for Controlled IL-12 in patients receiving low-dose...

Ziopharm Oncology Reports Second Quarter 2019 Financial Results

Ziopharm Oncology Reports Second Quarter 2019 Financial Results

- FDA Cleared IND for Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for  patients with solid tumors at the National Cancer Institute (NCI) - - Exclusive license from NCI for library of T-cell receptors (TCRs) targeting neoantigens in the hotspots...

Ziopharm Oncology To Host Conference Call To Discuss Second Quarter 2019 Results On August 8, 2019

Ziopharm Oncology To Host Conference Call To Discuss Second Quarter 2019 Results On August 8, 2019

BOSTON, July 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, August 8, at 8:30 a.

Ziopharm Oncology Announces $45 Million Warrant Exercise By Existing Shareholders In A Private Placement

Ziopharm Oncology Announces $45 Million Warrant Exercise By Existing Shareholders In A Private Placement

Provides capital to fund operations into 2021; warrant exercise in advance of November 2023 expiration

ZIOPHARM Oncology Reaches Analyst Target Price

ZIOPHARM Oncology Reaches Analyst Target Price

In recent trading, shares of ZIOPHARM Oncology Inc have crossed above the average analyst 12-month target price of $5.75, changing hands for $6.19/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ziopharm Oncology Names Sath Shukla As Chief Financial Officer

Ziopharm Oncology Names Sath Shukla As Chief Financial Officer

Joins from Vertex Pharmaceuticals; Served as global Head of Corporate Finance

Powell Apparently Looking for Reasons to Give the Market the Rate Cuts It Wants

Powell Apparently Looking for Reasons to Give the Market the Rate Cuts It Wants

Now the focus is on how many more cuts will follow.

Ziopharm Oncology Names NCI's Dr. Drew Deniger To Direct TCR-T Cell Therapy Program

Ziopharm Oncology Names NCI's Dr. Drew Deniger To Direct TCR-T Cell Therapy Program

- Dr. Deniger joins from National Cancer Institute to lead Ziopharm's non-viral T-cell program targeting neoantigens for personalized immunotherapy of solid tumors -

Interesting ZIOP Put And Call Options For August 16th

Interesting ZIOP Put And Call Options For August 16th

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

March 2021 Options Now Available For ZIOPHARM Oncology (ZIOP)

March 2021 Options Now Available For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options become available today, for the March 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 637 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ZIOPHARM Oncology Reaches Analyst Target Price

ZIOPHARM Oncology Reaches Analyst Target Price

In recent trading, shares of ZIOPHARM Oncology Inc have crossed above the average analyst 12-month target price of $5.75, changing hands for $6.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Interesting ZIOP Put And Call Options For March 15th

Interesting ZIOP Put And Call Options For March 15th

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new March 15th contracts and identified one put and one call contract of particular interest.

First Week Of ZIOP February 15th Options Trading

First Week Of ZIOP February 15th Options Trading

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

First Week Of ZIOP July 2019 Options Trading

First Week Of ZIOP July 2019 Options Trading

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the July 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of ZIOP November 16th Options Trading

First Week Of ZIOP November 16th Options Trading

Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

Interesting ZIOP Put And Call Options For January 2021

Interesting ZIOP Put And Call Options For January 2021

Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Interesting ZIOP Put And Call Options For April 2019

Interesting ZIOP Put And Call Options For April 2019

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the April 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of ZIOP September 21st Options Trading

First Week Of ZIOP September 21st Options Trading

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

ZIOPHARM Oncology Breaks Above 200-Day Moving Average - Bullish For ZIOP

In trading on Wednesday, shares of ZIOPHARM Oncology Inc crossed above their 200 day moving average of $4.72, changing hands as high as $4.88 per share. ZIOPHARM Oncology Inc shares are currently trading up about 9.7% on the day.

First Week Of June 15th Options Trading For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new June 15th contracts and identified one put and one call contract of particular interest.